Yoko Kubuki
Overview
Explore the profile of Yoko Kubuki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamiunten A, Kameda T, Sekine M, Kawano H, Toyama T, Akizuki K, et al.
Int J Hematol
. 2025 Mar;
PMID: 40067419
Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy with a poor prognosis. We conducted a retrospective study across six institutions in Miyazaki Prefecture, Japan, to assess the efficacy of...
2.
Chiba N, Suzuki S, Enriquez-Vera D, Utsunomiya A, Kubuki Y, Hidaka T, et al.
Heliyon
. 2024 Dec;
10(20):e38507.
PMID: 39640675
Adult T-cell leukemia/lymphoma (ATLL) is a refractory blood cancer with severe immunodeficiency resulting from retroviral infection. ATLL develops in only 5 % of HTLV-1-infected individuals, but the entire mechanism of...
3.
Usuki K, Kameda T, Kawano N, Ito T, Hashimoto Y, Shide K, et al.
Int J Hematol
. 2024 Mar;
119(6):722-727.
PMID: 38457113
Myeloid and lymphoid neoplasms associated with FGFR1 abnormalities (MLN-FGFR1 abnormalities) are rare hematologic malignancies associated with chromosome 8p11.2 abnormalities. Translocations of 8p11.2 were detected in 10 of 17,039 (0.06%) unique...
4.
Kameda T, Utsunomiya A, Otsuka N, Kubuki Y, Uchida T, Shide K, et al.
BMC Infect Dis
. 2024 Jan;
24(1):96.
PMID: 38233756
Background: Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown. Methods: To investigate humoral immunity after COVID-19 vaccination...
5.
Kameda T, Kataoka K, Kamiunten A, Hidaka M, Miyoshi H, Nakano N, et al.
Haematologica
. 2023 Feb;
108(8):2178-2191.
PMID: 36794502
The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment. In order to identify favorable prognostic patients after intensive...
6.
Kameda T, Shide K, Kamiunten A, Kogure Y, Morishita D, Koya J, et al.
Commun Biol
. 2022 Nov;
5(1):1309.
PMID: 36446869
Adult T-cell leukemia/lymphoma (ATL) is caused by human T-cell leukemia virus type 1 (HTLV-1). In addition to HTLV-1 bZIP factor (HBZ), a leukemogenic antisense transcript of HTLV-1, abnormalities of genes...
7.
Kameda T, Shide K, Tahira Y, Sekine M, Sato S, Ishizaki J, et al.
Viruses
. 2022 Apr;
14(4).
PMID: 35458440
A retrospective chart survey of the clinical features of indolent adult T-cell leukemia/lymphoma (ATL) was conducted in the Miyazaki Prefecture, Japan. This study enrolled 24 smoldering-type ATLs, 10 favorable chronic-type...
8.
Kogure Y, Kameda T, Koya J, Yoshimitsu M, Nosaka K, Yasunaga J, et al.
Blood
. 2021 Oct;
139(7):967-982.
PMID: 34695199
Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases...
9.
Koya J, Saito Y, Kameda T, Kogure Y, Yuasa M, Nagasaki J, et al.
Blood Cancer Discov
. 2021 Oct;
2(5):450-467.
PMID: 34661162
Significance: Our multimodal single-cell analyses comprehensively dissect the cellular and molecular alterations of the peripheral blood in HTLV-1 infection, with and without progression to leukemia. This study not only sheds...
10.
Akizuki K, Matsuoka H, Toyama T, Kamiunten A, Sekine M, Shide K, et al.
J Clin Med
. 2021 Jan;
10(1).
PMID: 33396800
The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents. These data are largely derived from clinical trials and might not reflect real-world patient outcomes accurately....